ProMab Biotechnologies has developed over 60 types of CAR-T/NK cells and target cells with several patented innovations in the CAR construct design. To further our pipeline of next-generation chimeric antigen receptor T-cell / NK-cell technology, we pushed forward to more methods of harnessing the power of the immune system. Our background in antibody engineering allowed us to create an established antibody discovery platform that reaps the benefits towards proprietary CAR technology.
ProMab is happy to announce we have made great strides in CAR-technology and are ready to share our knowledge towards custom CAR-macrophage development.
Background
By genetically engineering macrophages to express a CAR, it allows the macrophage the ability to recognize cancer cells more effectively, targeting specific antigens and thus triggering phagocytosis. Additionally, macrophages are able to directly present antigens to helper T-cells once they are activated and stimulate further response from the immune system.
Our custom development service for CAR-macrophages can be used to study the interaction of CAR-macrophages within the tumor micro-environment and study different agents (antibodies, cytokines, small molecules, etc). Our custom development package has been established for you to take direct advantage of our knowledge and platform.
ProMab can help you advance your ideas and technologies with two different plans:
Plan A
Generate the entire construct from a mouse monoclonal antibody or fully human single-chain variable antibody fragment (scFv) from our existing library.
| DEVELOPMENT STAGE | DESCRIPTION | Price |
|---|---|---|
| Phase I | Immunization of BALB/c mice with recombinant protein or carrier-conjugated peptide. Generation of hybridoma cell lines following antibody validation against the correctly-presented antigen. | $5,150 |
| Phase II | Sequencing of the antibody's heavy and light chains. | $1,600 |
| Phase III | Synthesis and cloning of an scFv with selected CAR domains into a lentivirus vector. Mid-scale generation of high titer (>1x108) lentivirus viral particles. | $8,500 |
| Phase IV | Macrophage-cell isolation, lentiviral transduction, and CAR-macrophage culture, CAR validation by FACS. | $7,500 |
| Phase IV-A | Phagocytosis Assay by flow cytometry to determine percentage of CAR-macrophage cells | $2,000 |
| Phase IV-B | Phagocytosis Assay by phase contrast microscopy to determine percentage of CAR-macrophage cells | $2,000 |
| Phase V | Cytokine release assay to measure IL-6, IL-10, and GM-CSF release during target cell engagement. | $4,000 |
For human antibody development, please inquire.
Plan B
Construct a CAR based on your antibody sequence.
| DEVELOPMENT STAGE | DESCRIPTION | PRICE |
|---|---|---|
| Phase III | Synthesis and cloning of an scFv with selected CAR domains into a lentivirus vector. Mid-scale generation of high titer (>1x108) lentivirus viral particles. | $8,500 |
| Phase IV | Macrophage-cell isolation, lentiviral transduction, and CAR-macrophage culture, CAR validation by FACS. | $7,500 |
| Phase IV-A | Phagocytosis Assay by flow cytometry to determine percentage of CAR-macrophage cells | $2,000 |
| Phase IV-B | Phagocytosis Assay by phase contrast microscopy to determine percentage of CAR-macrophage cells | $2,000 |
| Phase V | Cytokine release assay to measure IL-6, IL-10, and GM-CSF release during target cell engagement. | $4,000 |
From here, we can explore in-vivo efficacy using our in-house NSG/NOG xenograft model. Inquire for details.
Looking for more?
ProMab's 10 Components of the CAR-T/NK Platform
Current off-the-shelf CAR-T/NK solutions: